Search

Your search keyword '"Brenneman, Randall"' showing total 226 results
Start Over Author "Brenneman, Randall"
226 results on '"Brenneman, Randall"'

3. A Pilot Study of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MRI-Based and Online Adaptive Planning

Author

Kang, Kylie H., primary, Price, Alex T., additional, Reynoso, Francisco J., additional, Laugeman, Eric, additional, Morris, Eric D., additional, Samson, Pamela P., additional, Huang, Jiayi, additional, Badiyan, Shahed N., additional, Kim, Hyun, additional, Brenneman, Randall J., additional, Abraham, Christopher D., additional, Knutson, Nels C., additional, and Henke, Lauren E., additional

Published
2024
Full Text
View/download PDF

10. Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

Author

Roy, Amit, Brenneman, Randall J., Hogan, Jacob, Barnes, Justin M., Huang, Yi, Morris, Robert, Goddu, Sreekrishna, Altman, Michael, Garcia-Ramirez, Jose, Li, Harold, Zoberi, Jacqueline E., Bullock, Arnold, Kim, Eric, Smith, Zachary, Figenshau, Robert, Andriole, Gerald L., Baumann, Brian C., Michalski, Jeff M., and Gay, Hiram A.

Published
2021
Full Text
View/download PDF

12. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer

Author

Fischer-Valuck, Benjamin W., Rao, Yuan James, Brenneman, Randall J., Patel, Pretesh R., Filson, Christopher P., Jani, Ashesh B., Liu, Yuan, Goyal, Subir, Xu, Karen, Weiss, Aaron, Kucuk, Omer, Cimmino, Cara, Szabo, Stephen, Rossi, Peter, Baumann, Brian C., Pattaras, John, Hershatter, Bruce, and Patel, Sagar A.

Published
2020
Full Text
View/download PDF

13. CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer

Author

Waters, Michael, primary, Price, Alex, additional, Laugeman, Eric, additional, Henke, Lauren, additional, Hugo, Geoff, additional, Stowe, Hayley, additional, Andruska, Neal, additional, Brenneman, Randall, additional, Hao, Yao, additional, Green, Olga, additional, Robinson, Clifford, additional, Gay, Hiram, additional, Michalski, Jeff, additional, and Baumann, Brian C., additional

Published
2023
Full Text
View/download PDF

20. Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy

Author

Fischer-Valuck, Benjamin W., Patel, Sagar A., Brenneman, Randall J., Christodouleas, John, Sargos, Paul, Kim, Eric, Weiss, Aaron, Hershatter, Bruce, Rao, Yuan J., Picus, Joel, Roth, Bruce, Arora, Vivek, Carmona, Ruben, Reimers, Melissa, Zaghloul, Mohamed S., Gay, Hiram, Michalski, Jeff M., and Baumann, Brian C.

Subjects
Male, Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Oncology, Urology, Urinary Bladder, Humans, Female, Radiology, Nuclear Medicine and imaging, Surgery, Prospective Studies, Article, Retrospective Studies
Abstract

There are limited data on the role of local therapy for metastatic urothelial carcinoma of the bladder (mUC). In this retrospective cohort analysis, we queried the National Cancer Data Base for patients with newly diagnosed mUC (cT1-4 N0-3 M1). Overall survival (OS) was compared between treatment with chemotherapy (CT) alone (n = 4122) and CT plus bladder-directed radiation therapy (CT + RT; n = 337). Multivariable Cox proportional-hazards analyses and matching and landmark analyses were performed. CT + RT was independently associated with better OS (hazard ratio 0.70, 95% confidence interval 0.62-0.79; p0.0001) and this result persisted in matched and landmark analyses. These findings are hypothesis-generating and limited by inherent confounding factors; however, a prospective trial evaluating the impact of bladder RT in mUC is warranted. PATIENT SUMMARY: For patients with bladder cancer that has already spread to other parts of the body, it is unclear if radiation therapy directed at the primary bladder tumor would provide any improvement in survival. In this study, we found that aggressive radiation therapy directed at the bladder combined with chemotherapy may provide a survival benefit in some patients with metastatic bladder cancer compared to chemotherapy alone.

Published
2022

25. PSOR9 Presentation Time: 12:10 PM

Author

Patel, Sagar Anil, primary, Baumann, Brian C., additional, Michalski, Jeff M., additional, Gay, Hiram A., additional, Brenneman, Randall, additional, Chang, Albert J., additional, Rossi, Peter J., additional, and Fischer-Valuck, Ben W., additional

Published
2022
Full Text
View/download PDF

27. Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy

Author

Andruska, Neal, primary, Fischer-Valuck, Benjamin W., additional, Waters, Michael, additional, Juarez Diaz, Elizabeth, additional, Agabalogun, Temitope, additional, Kim, Eric H., additional, Smith, Zachary L., additional, Brenneman, Randall J., additional, Gay, Hiram A., additional, Andriole, Gerald L., additional, Michalski, Jeff M., additional, and Baumann, Brian C., additional

Published
2022
Full Text
View/download PDF

28. Reply by Authors

Author

Andruska, Neal, primary, Fischer-Valuck, Benjamin W., additional, Waters, Michael, additional, Juarez Diaz, Elizabeth, additional, Agabalogun, Temitope, additional, Kim, Eric H., additional, Smith, Zachary L., additional, Brenneman, Randall J., additional, Gay, Hiram A., additional, Andriole, Gerald L., additional, Michalski, Jeff M., additional, and Baumann, Brian C., additional

Published
2022
Full Text
View/download PDF

30. Assessing Inter-Fraction Changes in The Size and Position of The Penile Bulb During Daily MR-Guided Radiation Therapy to The Prostate Bed: Do We Need to Adjust How We Plan Radiation in The Post-Radical Prostatectomy Setting to Reduce Risk of Erectile Dysfunction?

Author

Roy, Amit, primary, Green, Olga, additional, Brenneman, Randall, additional, Bosch, Walter, additional, Gay, Hiram A, additional, Michalski, Jeff M., additional, and Baumann, Brian C., additional

Published
2022
Full Text
View/download PDF

32. Outcomes of Unfavorable Intermediate-Risk Prostate Cancer Patients Treated with External Beam Radiotherapy vs. Brachytherapy Alone

Author

Andruska, Neal, Fischer-Valuck, Benjamin W., Carmona, Ruben, Agabalogun, Temitope, Brenneman, Randall J., Gay, Hiram A., Michalski, Jeff M., and Baumann, Brian C.

Subjects
Article
Abstract

The NCCN Guidelines for Prostate Cancer currently recommend several definitive radiotherapy (RT) options for men with unfavorable intermediate-risk (UIR) prostate cancer: external-beam RT (EBRT) plus androgen deprivation therapy (ADT) or EBRT plus brachytherapy boost with or without ADT. However, brachytherapy alone with or without ADT is not well defined and is currently not recommended for UIR prostate cancer. We hypothesized that men treated with brachytherapy with or without ADT have comparable survival rates to men treated with EBRT with or without ADT.A total of 31,783 men diagnosed between 2004 and 2015 with UIR prostate cancer were retrospectively reviewed from the National Cancer Database. Men were stratified into 4 groups: EBRT (n=12,985), EBRT plus ADT (n=12,960), brachytherapy (n=4,535), or brachytherapy plus ADT (n=1,303). Inverse probability of treatment weighting (IPTW) was used to adjust for covariable imbalances, and weight-adjusted multivariable analysis (MVA) using Cox regression modeling was used to compare overall survival (OS) hazard ratios (HRs).Relative to EBRT alone, the following treatments were associated with improved OS: EBRT plus ADT (HR, 0.92; 95% CI, 0.87-0.97; P=.002), brachytherapy alone (HR, 0.90; 95% CI, 0.83-0.98; P=.01), and brachytherapy plus ADT (HR, 0.78; 95% CI, 0.69-0.88; P=.00006). Brachytherapy correlated with improved OS relative to EBRT in men who were not treated with ADT (HR, 0.92; 95% CI, 0.84-0.99; P=.03) and in those receiving ADT (HR, 0.84; 95% CI, 0.75-0.95; P=.004). At 10-year follow-up, 56% and 63% of men receiving EBRT and brachytherapy, respectively, were alive (P.0001). IPTW was used to determine the average treatment effect of definitive brachytherapy. Relative to EBRT, definitive brachytherapy correlated with improved OS (HR, 0.90; 95% CI, 0.84-0.97; P=.009) on weight-adjusted MVA.Definitive brachytherapy was associated with improved OS compared with EBRT. The addition of ADT to both EBRT and definitive brachytherapy was associated with improved OS. These results suggest that definitive brachytherapy should be considered as an option for men with UIR prostate cancer.

Published
2022

33. Is the addition of brachytherapy and/or androgen deprivation therapy associated with improved overall survival in unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy?

Author

Andruska, Neal, Fischer-Valuck, Benjamin W., Carmona, Ruben, Agabalogun, Temitope, Brenneman, Randall J., Gay, Hiram A., Michalski, Jeff M., and Baumann, Brian C.

Subjects
Male, Brachytherapy, Androgens, Humans, Prostatic Neoplasms, Androgen Antagonists, Article, Retrospective Studies
Abstract

BACKGROUND: Current recommendations regarding radiotherapy treatment for unfavorable intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT) ± brachytherapy boost (BT) ± androgen deprivation therapy (ADT). The ideal radiotherapy treatment approach for UIR-PCa has not been well-defined. We hypothesized that EBRT+BT±ADT is associated with improved overall survival (OS) relative to EBRT±ADT in men with UIR-PCa. MATERIALS AND METHODS: The National Cancer Database (NCDB) was used to retrospectively identify 32,246 men diagnosed between 2004–2015 with UIR-PCa who received EBRT (n=13,265), EBRT+ADT (n=13,123), EBRT+BT (n=3,440), or EBRT+BT+ADT (n=2,418). OS was the primary outcome. Inverse probability of treatment weighting was used to adjust for covariable imbalances and weight-adjusted multivariable analysis (MVA) using Cox regression modeling was used to compare OS hazard ratios. RESULTS: Median follow-up was 60 months (range: 3–168 months). EBRT+ADT correlated with improved OS relative to EBRT alone on MVA (Hazard Ratio (HR): 0.92, [95% Confidence Interval: 0.87–0.98], p=.005). Compared to EBRT+ADT, EBRT+BT (HR: 0.77 [0.69–0.85], p=3×10(−7)) and EBRT+BT+ADT (HR: 0.75 [0.67–0.83], p=6×10(−8)) were associated with improved OS. 8-year OS for the EBRT+ADT versus EBRT+BT+ADT was 70% and 78% (p

Published
2022

34. Risk Factors for Functional Outcomes in Advanced Laryngeal Squamous Cell Carcinoma.

Author

Lee, David S., Lee, Jake J., Sinha, Parul, Puram, Sidharth V., Jackson, Ryan S., Adkins, Douglas R., Oppelt, Peter, Brenneman, Randall, Thorstad, Wade L., and Pipkorn, Patrik

Abstract

Objective: Chemoradiation for patients with laryngeal squamous cell carcinoma (SCC) may achieve organ preservation, but appropriate patient selection remains unknown. This study investigates pre‐treatment risk factors associated with functional and survival outcomes after radiation‐based therapy in patients with advanced laryngeal SCC. Methods: A retrospective cohort study was performed on 75 adult patients with stage III or IV laryngeal SCC receiving definitive radiation‐based therapy from 1997 to 2016 at a tertiary care center. Tracheostomy and gastrostomy dependence were the primary functional outcomes. Multivariable logistic regressions were performed to evaluate relationships between pre‐treatment factors and tracheostomy and gastrostomy dependence. Time‐to‐event analyses were performed to determine risk factors associated with overall survival. Results: Among 75 patients included in the analysis, 30 (40%) patients were tracheostomy dependent and 31 (41%) were gastrostomy tube dependent. The median length of follow‐up was 31 months (range = 1 to 142 months). Pre‐treatment tracheostomy was a significant predictor of post‐treatment tracheostomy (aOR = 13.9, 95% CI = 3.35 to 57.5) and moderate–severe comorbidity was a significant predictor of post‐treatment gastrostomy dependence (aOR = 2.96, 95% CI = 1.04 to 8.43). The five‐year overall survival was 51% (95% CI = 38 to 64%). Pre‐treatment gastrostomy tube dependence was associated with an increased risk of death (aHR = 2.45, 95% CI = 1.09 to 5.53). Conclusions: Baseline laryngeal functional status and overall health in advanced laryngeal SCC are associated with poor functional outcomes after radiation‐based therapy, highlighting the importance of patient selection when deciding between surgical and non‐surgical treatment plans. Laryngoscope, 133:594–600, 2023 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Stereotactic body radiation therapy (SBRT) versus conventionally fractionated external beam radiation therapy in unfavorable intermediate-risk prostate cancer: An inverse propensity matched analysis.

Author

Andruska, Neal, primary, Fischer-Valuck, Benjamin Walker, additional, Agabalogun, Temitope, additional, Carmona, Ruben, additional, Brenneman, Randall, additional, Gay, Hiram Alberto, additional, Michalski, Jeff M., additional, and Baumann, Brian Christopher, additional

Published
2021
Full Text
View/download PDF

43. PRSOR07 Presentation Time: 12:30 PM

Author

Roy, Amit, primary, Brenneman, Randall J., additional, Hogan, Jake, additional, Barnes, Justin, additional, Huang, Yi, additional, Morris, Robert, additional, Goddu, S. Murty, additional, Michael, Altman, additional, Garcia-Ramirez, Jose, additional, Li, Harold, additional, Zoberi, Jacqueline E., additional, Bullock, Arnold, additional, Kim, Eric, additional, Smith, Zachary, additional, Figenshau, Robert, additional, Andriole, Gerald, additional, Baumann, Brian, additional, Michalski, Jeff, additional, and Gay, Hiram, additional

Published
2021
Full Text
View/download PDF

46. PLEN02 Presentation Time: 1:30 PM

Author

Fischer-Valuck, Benjamin W., primary, Patel, Kirtesh, additional, Andruska, Neal, additional, Baumann, Brian C., additional, Michalski, Jeff M., additional, Dhere, Vishal, additional, Brenneman, Randall, additional, Gay, Hiram A., additional, Hershatter, Bruce, additional, and Patel, Sagar A., additional

Published
2021
Full Text
View/download PDF

47. PRSOR01 Presentation Time: 12:00 PM

Author

Andruska, Neal D., primary, Michalski, Jeff M., additional, Agabalogun, Temitope, additional, Brenneman, Randall J., additional, Gay, Hiram A., additional, Fischer-Valuck, Benjamin W., additional, and Baumann, Brian C., additional

Published
2021
Full Text
View/download PDF

50. Regional lymph node irradiation in locally advanced Merkel cell carcinoma reduces regional and distant relapse and improves disease-specific survival

Author

Andruska, Neal, primary, Mahapatra, Lily, additional, Brenneman, Randall J., additional, Huang, Yi, additional, Paniello, Randal C., additional, Puram, Sidharth V., additional, Mansour, Mena, additional, Rich, Jason T., additional, Baumann, Brian C., additional, Thorstad, Wade L., additional, and Daly, Mackenzie D., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results